Publikationen, an denen er mitarbeitet José Hernández Quero (17)

2023

  1. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

2022

  1. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

2019

  1. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status

    Cells, Vol. 7, Núm. 11

  2. Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

  3. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

2013

  1. Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 5, pp. 304-312

2012

  1. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists

    AIDS Reviews, Vol. 14, Núm. 3, pp. 208-217

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy

    Current HIV Research, Vol. 6, Núm. 2, pp. 100-107

2004

  1. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis